fbpx

Mubadala Capital Partakes in USD 200 Million Investment into Tenvie Therapeutics

Mubadala Capital Partakes in USD 200 Million Investment into Tenvie Therapeutics
Image Source: Pexels
  • Mubadala Capital partakes in USD 200 million investment alongside ARCH Venture Partners, F-Prime Capital, and other investors in Tenvie Therapeutics.
  • The biotechnology company seeks to profoundly advance neurological disease treatment, significantly impacting patients’ lives and their families.
  • Tenvie aims to use this investment to become a multi-clinical asset company.

Mubadala Capital, based in the UAE, joins ARCH Venture Partners, F-Prime Capital, and others in a USD 200 million investment into Tenvie Therapeutics. This investment aims to accelerate Tenvie into a multi-clinical asset company.

As a biotechnology company based in San Francisco, Tenvie Therapeutics launched on the 8th of January 2025. They launched with a commitment to transforming and advancing the treatment of neurological, cardiometabolic, and ophthalmic diseases.

Tenvie was founded to fundamentally alter the treatment paradigm for neurological diseases and profoundly impact the lives of patients, their families, and caregivers.

Tony Estrada, President and Chief Scientific Officer at Tenvie

Tenvie assembled a team of experts in fields ranging from neurology, CNS development, small molecule chemistry, transnational medicine and business operations. This expert team boasts a proven track record of developing therapies for central nervous system and peripheral diseases. The most recent addition to their Board of Directors is Alaa Halawa, a representative from Mubadala Capital. 

Stacie Weninger, Venture Partner at F-Prime Capital states that, “Led by CNS drug developers with proven track records in advancing molecules from discovery to clinical validation, Tenvie is set to lead the next generation of neurology treatments.”

With this investment and its expert team, Tenvie is poised to advance neurological treatment and become a multi-clinical asset company.

If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.